Doppel Farmaceutici is an Italian Company operating in the pharmaceutical market with competence, seriousness and reliability, since 1995. Since the beginning, Doppel chose to be a “Partner in Outsourcing” for its Customers, able to take care of the whole life of Customer’s products (from the formulation, to development, up to marketing and post-marketing controls and analysis). Doppel can also support its Customers offering services, products and advice complementary to pharmaceutical production.
Contact
Registered Office
via Martiri delle Foibe 1
29016 Cortemaggiore
(PC), Italy
via Volturno 48
20089 Rozzano
(MI), Italy
phone +39 02 822711
fax +39 02 82271245
Lilly’s president and general manager for its Italy hub, Huzur Devletsah, explains the company’s broad footprint in the country – where Lilly maintains a large manufacturing site that produces over…
Gilead Sciences’ vice president and general manager for Italy, Valentino Confalone, outlines the company’s tumultuous pandemic journey in one of the first global epicentres; the role that Italy played in…
The latest news from the Italian healthcare and life sciences industries, including the final piece in Angelini’s updated leadership team; the country’s digital health investment timetable; and the details of…
Formerly known as Assogenerici, Egualia is an Italian industry association representing generics and biosimilar companies. Michele Uda, its director-general, speaks about the industry’s impressive response to the COVID-19 pandemic and…
With advances in technology, an increasing number of stable peptide-based therapeutics are being brought to market today across a wide range of therapeutic areas. Through expert insight, we explain why…
Speaking recently to PharmaBoardoom, Assobiotec’s Leonardo Vingiani introduced the key dynamics shaping the Italian biotech industry today and the issues it still has to overcome to become truly globally competitive.…
Assobiotec’s Leonardo Vingiani introduces the key trends shaping the Italian biotech ecosystem today, the steps that the country’s government have taken to foster life sciences innovation, and the areas in…
Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches…
In recent months, a profound transformation has been occurring right at the core of the Italian pharmaceutical industry as the most significant reforms to market access within two decades start…
The latest Italy Pharma News, including the government’s decision to make COVID-19 vaccines mandatory for all healthcare workers, the manufacturing of Sputnik V, and recent updates from the country’s top…
The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine contracts, glass vial manufacturer Stevenato’s USD five billion valuation, AIFA’s approval of Novartis’s Zolgensma, and…
A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with Menarini CEO Elcin Barker Ergun, a public health management crisis in the…
See our Cookie Privacy Policy Here
